SELLAS Life Sciences Group, Inc.
SLSNASDAQHealthcareBiotechnology
Previous close
$15.46
+$2.06 · +15.37%
Pre-market
$15.62
+$0.16 · +1.03%
Aug 24, 6:37 AM ET
SLS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
40
Expensive
Momentum
72
Gaining
Sentiment
68
Bullish
Risk resilience
39
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Angelos Stergiou
- Listed since
- Mar 12, 2008
- Employees
- 13
Market position
Day range
Current $15.46
52-week range
Current $15.46
- Open
- $13.64
- Previous close
- $13.40
- Volume
- 15.24M
- 1.81× average
- Average volume
- 8.42M
- Average daily volume
- Market cap
- 2.88B USD
- Beta
- 2.49
- Market reference 1
- 50-day average
- $11.6974
- +32.17% above average
- 200-day average
- $6.1849
- +149.96% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 340.23M USD
- P/E (TTM)
- -73.17×
- P/B (TTM)
- 21.25×
- P/S (TTM)
- 0×
- EV / EBITDA
- -12.67×
- Earnings yield
- -6.53%
- Free cash flow yield
- -6.91%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -37.90%
- Return on assets
- -34.29%
- Return on invested capital
- -39.34%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 10.72×
Earnings
- EPS beat rate
- 73%
- 8 beats, 3 misses, 0 met estimates
- Average EPS surprise
- -24.79%
- 11 comparable reports
- Latest EPS result
- -0.05
- Estimate -0.05 · Miss by 11.11%
EPS: actual versus estimate
Recent quarterly results
SLS news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 8, 2019 | 1:50 | — | — |
Stock split | Jan 2, 2018 | 1:30 | — | — |
Stock split | Nov 14, 2016 | 1:20 | — | — |
Effective Nov 8, 2019
1:50
Effective Jan 2, 2018
1:30
Effective Nov 14, 2016
1:20
SLS peers
Continue in GoAI
Research SLSresearch.disclaimer